|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:MLLT10-CACNA2D3 (FusionGDB2 ID:HG8028TG55799) |
Fusion Gene Summary for MLLT10-CACNA2D3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MLLT10-CACNA2D3 | Fusion gene ID: hg8028tg55799 | Hgene | Tgene | Gene symbol | MLLT10 | CACNA2D3 | Gene ID | 8028 | 55799 |
| Gene name | MLLT10 histone lysine methyltransferase DOT1L cofactor | calcium voltage-gated channel auxiliary subunit alpha2delta 3 | |
| Synonyms | AF10 | HSA272268 | |
| Cytomap | ('MLLT10')('CACNA2D3') 10p12.31 | 3p21.1-p14.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein AF-10ALL1-fused gene from chromosome 10 proteinmyeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10type I AF10 proteintype III AF10 prot | voltage-dependent calcium channel subunit alpha-2/delta-3calcium channel alpha2-delta3 subunitcalcium channel, voltage-dependent, alpha 2/delta 3 subunitcalcium channel, voltage-dependent, alpha 2/delta subunit 3voltage-gated calcium channel subunit a | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P55197 | Q8IZS8 | |
| Ensembl transtripts involved in fusion gene | ENST00000377091, ENST00000377100, ENST00000307729, ENST00000377059, ENST00000377072, ENST00000446906, ENST00000495130, | ||
| Fusion gene scores | * DoF score | 18 X 15 X 10=2700 | 16 X 13 X 9=1872 |
| # samples | 24 | 16 | |
| ** MAII score | log2(24/2700*10)=-3.49185309632968 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(16/1872*10)=-3.54843662469604 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: MLLT10 [Title/Abstract] AND CACNA2D3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | MLLT10(21845858)-CACNA2D3(54660646), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MLLT10 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 17868029 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for MLLT10-CACNA2D3 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for MLLT10-CACNA2D3 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for MLLT10-CACNA2D3 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:21845858/:54660646) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MLLT10 | CACNA2D3 |
| FUNCTION: Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. In cells, binding to unmodified histone H3 regulates DOT1L functions including histone H3 'Lys-79' dimethylation (H3K79me2) and gene activation (PubMed:26439302). {ECO:0000269|PubMed:17868029, ECO:0000269|PubMed:26439302}. | FUNCTION: The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for MLLT10-CACNA2D3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for MLLT10-CACNA2D3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MLLT10-CACNA2D3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CACNA2D3 | Q8IZS8 | DB00381 | Amlodipine | Inhibitor | Small molecule | Approved |
| Tgene | CACNA2D3 | Q8IZS8 | DB06712 | Nilvadipine | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for MLLT10-CACNA2D3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | MLLT10 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | MLLT10 | C0025202 | melanoma | 1 | CTD_human |
| Hgene | MLLT10 | C0025286 | Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0205834 | Meningiomas, Multiple | 1 | CTD_human |
| Hgene | MLLT10 | C0259785 | Malignant Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | MLLT10 | C0281784 | Benign Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334605 | Meningothelial meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334606 | Fibrous Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334607 | Psammomatous Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334608 | Angiomatous Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334609 | Hemangioblastic Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334610 | Hemangiopericytic Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0334611 | Transitional Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0347515 | Spinal Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0349604 | Intracranial Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0431121 | Clear Cell Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0457190 | Xanthomatous Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0751303 | Cerebral Convexity Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C0751304 | Parasagittal Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | MLLT10 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | MLLT10 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| Hgene | MLLT10 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | MLLT10 | C1334261 | Intraorbital Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1334271 | Intraventricular Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1335107 | Olfactory Groove Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1384406 | Secretory meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1384408 | Microcystic meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1527197 | Angioblastic Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1565950 | Posterior Fossa Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1565951 | Sphenoid Wing Meningioma | 1 | CTD_human |
| Hgene | MLLT10 | C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | ORPHANET |
| Hgene | MLLT10 | C3163622 | Papillary Meningioma | 1 | CTD_human |
| Tgene | C1535926 | Neurodevelopmental Disorders | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies